Abbvie Inc Stock Price, News & Analysis

AbbVie (ABBV) announced new results from two ongoing clinical trials of epcoritamab in patients with diffuse large B-cell lymphoma (DLBCL). The Phase 1b/2 EPCORE NHL-2 trial showed 100% overall response rate and 87% complete response rate in untreated high-risk DLBCL patients when combined with R-CHOP therapy. Among complete responders, 83% remained in remission after two years.

The Phase 2 EPCORE NHL-1 trial's three-year follow-up, evaluating epcoritamab monotherapy in relapsed/refractory patients, demonstrated 59% overall response rate and 41% complete response rate. Among complete responders, 52% maintained response at three years, with median complete response duration of 36.1 months.

AbbVie announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating tavapadon as a flexible-dose monotherapy in early Parkinson's disease. The trial met its primary endpoint, showing a statistically significant improvement from baseline in the MDS-UPDRS Parts II and III combined score at week 26 compared to placebo (placebo: -1.2; tavapadon 5-15 mg: -10.3; p-value <0.0001). Additionally, it achieved its key secondary endpoint with a significant improvement in motor aspects of daily living (MDS-UPDRS Part II) at week 26. The safety profile was consistent with prior trials, with the majority of adverse events being mild to moderate. AbbVie is on track to submit a New Drug Application (NDA) for tavapadon to the FDA in 2025.

AbbVie released its latest Emotional Impact Report (EIR) at the 66th ASH Annual Meeting, revealing groundbreaking insights into the mental health impacts of chronic lymphocytic leukemia (CLL) on underrepresented patients. The study, involving 232 participants, shows that Black, Hispanic, and Asian patients face unique emotional challenges throughout their cancer journey.

Key findings indicate that ethnically diverse patients strongly desire culturally tailored support resources (45% Asian, 38% Hispanic, 24% Black) compared to 2% of Caucasian respondents. These groups also report higher concerns about financial challenges (35% Black, 39% Asian, 53% Hispanic vs 18% Caucasian). Less than half of all surveyed patients feel supported by their doctors in managing emotional impact, with particularly low rates among Asian (29%), Black (30%), and Hispanic (38%) patients.

AbbVie (ABBV) announced updated results from the Phase 1b/2 EPCORE® NHL-2 trial evaluating epcoritamab plus lenalidomide + rituximab (R2) in patients with relapsed or refractory follicular lymphoma (FL). The trial showed impressive results with a 96% overall response rate and 87% complete response rate among 111 patients with over two years median follow-up.

At 18 months, an estimated 89% of complete responders maintained their response, and 88% of patients showed no detectable disease in minimal residual disease analysis. The most common treatment-emergent adverse events were neutropenia (62%) and cytokine release syndrome (51%). The FDA recently granted breakthrough therapy designation for this combination therapy.

Satellos Bioscience (TSX:MSCL, OTCQB:MSCLF) announces participation in a live investor webinar focused on Duchenne muscular dystrophy (DMD) on December 4, 2024, at 2:00 pm ET. The webinar will feature key opinion leaders discussing three main topics: new treatment approaches for DMD, patient navigation of clinical trials, and Satellos' novel small molecule approach focusing on muscle regeneration.

Featured speakers include Elijah Stacy, a DMD patient advocate and Founder of Destroy Duchenne, Dr. Michael Rudnicki, Scientific Founder of Satellos and Director of Regenerative Medicine at Ottawa Hospital Research Institute, and Dr. Jordan Dubow, Satellos' CMO. The event will include a Q&A session and is free to attend.

AbbVie (NYSE: ABBV) has announced its participation in Citi's 2024 Global Healthcare Conference scheduled for Tuesday, December 3, 2024. The company will be represented by three executive leaders: Scott T. Reents (CFO), Jeffrey R. Stewart (CCO), and Dr. Roopal Thakkar (EVP of R&D and CSO), who will present at 9:15 a.m. Central time.

The presentation will be accessible via live audio webcast through AbbVie's Investor Relations website, with an archived version available later that day.

Allergan Aesthetics, an AbbVie company, has launched AMI Business Education, offering free online business training courses through the AMI Online platform. The initiative includes seven new e-trainings, each under 30 minutes, designed to help healthcare practitioners enhance their practice management with Allergan Aesthetics products. The curriculum covers key areas including practice success ingredients, goal setting, telephone lead conversion, and patient partnership development. The program aims to support practitioners in balancing clinical excellence with business operations, providing practical tools for sustainable growth and practice management efficiency.

AbbVie (ABBV) has received European Commission approval for ELAHERE® (mirvetuximab soravtansine) to treat platinum-resistant ovarian cancer in adult patients with folate receptor-alpha positive disease who have received one to three prior systemic treatments. This marks the first FRα-directed antibody drug conjugate approved in the EU and associated regions.

The approval is supported by the Phase 3 MIRASOL trial results, which showed a 35% reduction in tumor progression or death risk and a 33% reduction in death risk compared to chemotherapy. The companion diagnostic VENTANA FOLR1 RxDx Assay also received CE Mark approval to identify eligible patients.

AbbVie (NYSE: ABBV) has announced 20 winners of the inaugural AbbVie Migraine Career Catalyst Award™ contest, supporting career aspirations of people living with migraine. The winners, selected through essay, video, and audio submissions, represent diverse professions including engineers, scientists, teachers, and artists. The initiative addresses the significant impact of migraine on careers, noting that nearly 40 million Americans live with this debilitating neurological disease, resulting in over 113 million work days lost annually in the U.S. Winners will receive support to pursue their professional goals while managing migraine symptoms, demonstrating that career ambitions can extend beyond the disease's impact.